Opsan Healthtech Private Limited

Fondaparinux Sodium 7.5 mg/0.6 ml Injection
(Brand names: Arixtra®, Fondaflo®, Fondared®, etc.)

Synthetic Selective Factor Xa Inhibitor (Anticoagulant)

Fondaparinux binds to antithrombin III, enhancing its activity and inhibiting Factor Xa specifically.

• Inhibits thrombin generation

• Prevents clot formation

Unlike unfractionated heparin (UFH) and low molecular weight heparins (LMWHs), it does not inhibit thrombin (Factor IIa) and has no effect on platelets, minimizing the risk of HIT (Heparin-induced thrombocytopenia).

Primarily used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).

✅ Used in combination with warfarin or other oral anticoagulants to bridge therapy.

The dose is weight-based:

• <50 kg: 5 mg once daily SC

• 50–100 kg: ✅ 7.5 mg once daily SC

• >100 kg: 10 mg once daily SC

🕑 Administered subcutaneously once daily.

• Typically used for 5 to 9 days, followed by transition to long-term oral anticoagulation (e.g., warfarin, DOACs)

Common:

• Bleeding (most significant)

• Anemia

• Injection site pain or bruising

Rare:

• Thrombocytopenia

• Elevated liver enzymes

• Hypersensitivity reactions

• Active major bleeding

• Severe renal impairment (CrCl < 30 mL/min)

• Body weight <50 kg

• Bacterial endocarditis

• Recent neuraxial anesthesia or spinal puncture

• No need for routine coagulation monitoring (unlike heparin)

• Check:

  • Renal function (prior and during therapy)

  • Signs/symptoms of bleeding

  • Platelet count (if used long term)

• Approx. ₹2,200 – ₹3,000 per pre-filled syringe

• Significantly cheaper compared to US or Europe, where it can cost $150–$300 per dose.

• Store at room temperature (2°C–25°C)

• Do not freeze

• Single-use only

Gefitinib 250 mg Tablets - Medical Description
Generic Name: Gefitinib  Brand Name: Iressa
Formulation:  Gefitinib is available in oral tablet form, with a common strength of 250 mg per tablet.
Indications:  Gefitinib is primarily used for the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations:- Non-Small Cell Lung Cancer (NSCLC): It is used in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor (EGFR) mutations, particularly for those who have failed chemotherapy.- EGFR Mutations: Gefitinib is specifically indicated for patients with tumors that have activating mutations in the EGFR gene, which encodes a protein involved in cell growth.
Mechanism of Action:  Gefitinib is an EGFR (epidermal growth factor receptor) inhibitor. It works by targeting and blocking the EGFR tyrosine kinase, a protein that is involved in the signaling pathways that promote the growth and survival of cancer cells. By inhibiting EGFR, Gefitinib can prevent cancer cells from growing and dividing, thus inhibiting tumor growth.
Dosage and Administration:  The typical dose for Gefitinib is:- 250 mg once daily, taken orally, with or without food.- It is important to take the tablet at the same time every day to maintain consistent levels in the body.
Patients should swallow the tablet whole and not crush or chew it.
Side Effects:  Common side effects of Gefitinib include:- Diarrhea- Rash (often acne-like, especially on the face and chest)- Dry skin or skin reactions- Nausea and vomiting- Loss of appetite- Fatigue- Liver enzyme elevations (which may require monitoring of liver function)
Serious side effects can include:- Interstitial lung disease (ILD): This is a serious condition where the lungs become inflamed, which can cause difficulty breathing, coughing, and other respiratory issues. It can be fatal and requires immediate medical attention.- Severe eye problems (e.g., eye irritation, dry eyes, or inflammation)- Liver problems: Symptoms of liver dysfunction may include yellowing of the skin or eyes (jaundice), dark urine, or upper stomach pain.- Gastrointestinal perforation (rare but serious, involves holes in the digestive tract)
Precautions and Warnings:- Lung Disease (ILD): Patients should be monitored for symptoms of lung problems, including shortness of breath, dry cough, or chest pain, which may indicate ILD.- Liver Function: Liver function should be regularly monitored during treatment as Gefitinib can cause liver toxicity.- Pregnancy and Breastfeeding: Gefitinib should not be used during pregnancy, as it can harm the unborn child. It is also not recommended during breastfeeding, as it is not known whether the drug is excreted in human milk.- Drug Interactions: Gefitinib can interact with other medications that alter liver enzymes, including certain antibiotics, antifungals, and antiepileptics. Always inform the healthcare provider of any other medications being used.

Etoposide 50mg Tablets – Medical Description

Generic Name: Etoposide
Brand Name: Various (including VePesid, Etopophos, among others)

Class: Antineoplastic agent, Chemotherapy drug

Dosage Form: Tablet

Strength: 50mg per tablet

Indications:
Etoposide is primarily used for the treatment of various types of cancer, including:

• Small cell lung cancer (SCLC)
• Testicular cancer
• Non-Hodgkin lymphoma
• Leukemia
• Ovarian cancer (less commonly)
• Kaposi's sarcoma (in HIV-positive individuals)

Mechanism of Action:
Etoposide works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication. By interfering with this enzyme, etoposide prevents the cancer cells from replicating and leads to their death. This is why it is effective as a chemotherapy agent.

Administration:

• Typically administered orally in tablet form, usually once or twice daily, as directed by the healthcare provider.
• Can be taken with or without food, but should be swallowed whole and not crushed or chewed.
• Dosing may vary based on the type of cancer being treated, the patient's overall health, and response to treatment.

Common Side Effects:

• Nausea and vomiting
• Hair loss
• Diarrhea
• Decreased white blood cell count (increasing risk of infection)
• Fatigue
• Loss of appetite

Serious Side Effects:

• Severe allergic reactions (e.g., rash, swelling, trouble breathing)
• Low blood pressure (hypotension)
• Liver or kidney issues
• Blood clotting problems (bleeding or bruising)
• Secondary cancers (in rare cases, as a long-term effect)

Contraindications:

• Known hypersensitivity (allergy) to etoposide or any of its components
• Severe liver or kidney impairment (dosing adjustments may be needed)
• Pregnancy (category D: may harm the fetus, should not be used during pregnancy unless clearly necessary)

Precautions:

• Regular monitoring of blood counts is essential during treatment due to the potential for bone marrow suppression.
• Etoposide can cause low blood pressure, so it is important to monitor vital signs during administration, especially in the case of intravenous use.
• Patients should avoid live vaccines during treatment, as their immune systems may be weakened.

Drug Interactions:

• Corticosteroids: May increase the risk of certain side effects.
• Warfarin: Etoposide may increase the anticoagulant effects, increasing the risk of bleeding.
• CYP3A4 inhibitors/inducers: These drugs may alter the metabolism of etoposide and affect its efficacy or increase side effects.

Pregnancy Category: D (Risk to fetus; benefits may outweigh the risk in some cases)

Lactation: Etoposide should not be used during breastfeeding, as it can pass into breast milk and harm the infant.

Storage:
Store at room temperature (15°C to 30°C / 59°F to 86°F) in a tightly closed container. Keep away from moisture and heat. Keep out of reach of children.

Always follow the prescribing physician's instructions, and if any severe side effects or allergic reactions occur, seek medical help immediately.